Aussie rules: 'Game-changing' 3D cell culture developer looks to expand US footprint, raises $25m –

Or wait…

Bio Developments
Upstream Processing
Downstream Processing
Markets & Regulations
Biopharma Culture
Promotional Features
Site Archive
Hot Topics
Antibody-Drug Conjugates
Emerging Markets
Cell & Gene Therapies
Site Archive
Type of resources
All Events
Online Events
Editorial Webinars
Shows & Conferences
Related Site
By Jane Byrne contact
16-Dec-2021 – Last updated on 16-Dec-2021 at 16:35 GMT
Related tags: Cell culture, Drug discovery
function sanitize_gpt_value2(gptValue)
var vOut=””;
var aTags = gptValue.split(‘,’);
var reg = new RegExp(‘\W+’, “g”);

for (var i=0; i < aTags.length; i++)
vOut += aTags[i].trim().replace(reg, '-').substring(0,40);
vOut +=', ';

vOut = vOut.toLowerCase();
return vOut;

$(document).ready(function() {
dataLayerNews = {};

dataLayerNews.related_tags = sanitize_gpt_value2("Cell culture, Drug discovery");

This Series B round brings the firm’s total funding to date to US$32m. It also included significant re-investment from Skip Capital, confirmed the Sydney headquartered innovator.
The financing, said Inventia, will enable it to scale up and market its RASTRUM 3D cell culture platform worldwide and grow its team from 36 to 150 employees by the end of 2024. In particular, it is looking to develop a strong presence in the US.
Niki Scevak, partner at Blackbird Ventures, said Inventia’s 3D cell culture technology has the potential to improve cancer and other cellular research in a fundamental way.
When asked how Inventia will go about growing its presence in the US, CEO, Dr Julio Ribeiro, told us:
“We have a strong customer pipeline of pending orders in the US (as well as in Europe and APAC). We have recently appointed Dr Dwayne Dexter as our US director of sales to lead the expansion of our US footprint and presence. As a veteran in the life science industry, he will be instrumental in building our support and go-to-market team in the US and growing our partnerships with pharmaceutical and academic customers.”
In terms of how the company’s RASTRUM 3D cell culture platform differs from competitor models, he noted how multiple other companies have developed great bioprinting products that enable tissue engineers to design and create their own biological tissues and organs. 
Unlike traditional 3D bioprinters and competitor models, though, RASTRUM uses proprietary technology in drop-on-demand bioprinting, enabling consistent and reproducible production of 3D cell cultures at scale. At the core of the drop-on-demand technology is the ability to print tiny droplets of cells and matrix components in a way that is very precise and gentle on the cells. This enables any biologist to print 3D cell cultures with unprecedented speed and reproducibility, replacing a time-consuming and manual process of traditional 3D cell culture generation. It is a real game changer,” ​said the CEO.

How can the platform enable new approaches to cancer research, and the development and validation of new drugs?
Since 3D cell cultures better represent human tissue, they also more accurately replicate biological processes and drug responses. The RASTRUM platform enables the creation of reproducible 3D cell cultures in formats that are compatible with standard drug discovery workflows and analysis methods, meaning the power of 3D cell cultures can be harnessed in a simple-to-embed platform.
“These 3D cell cultures recapitulate the in vivo characteristics of the native microenvironment in a tissue- and disease- specific manner. When used to print diseased or healthy cells, the platform enables rapid testing of new therapies on realistic models mimicking native cell behavior and response, without the use of animal models.
“RASTRUM prints tailored biomaterials that gel instantly to embed cells in a physiologically-relevant matrix environment with similar stiffness and biofunctional properties of human tumors. The speed and reproducibility of 3D cell culture generation that RASTRUM enables means that cancerresearchers, for example, can confidently conduct significantly more experiments in 3D — effectively accelerating their research and into identifying novel disease treatments,” ​reported Ribeiro.
There has been great initial uptake of the platform in both the academic and industrial sectors, he said. 
“Within the academic market, it is currently being used by over 20 universities and world leading research institutes in Australia, the US and Europe.
“But we have also had strong interest from drug discovery companies and contract research organizations (CROs).
“We installed the first US platform in November 2020 at a leading CRO in San Diego and this year entered partnerships with two of the 10 largest pharmaceutical companies to develop targeted complex disease models.”​ 
Copyright – Unless otherwise stated all contents of this web site are © 2021 – William Reed Business Media Ltd – All Rights Reserved – Full details for the use of materials on this site can be found in the Terms & Conditions
Related topics: Markets & Regulations, Analytical (technologies & services)
Show more
Maximize lab productivity and quality by embracing expected ICH Q14 Enhanced Method Development Guidelines and AQbD approaches
Recorded the 12-Oct-2021 | Webinar
Upcoming ICH Q14 Guidelines are an opportunity for Contract Service Providers to embrace enhanced approaches to method development such as Analytical Quality…
Register for free
Tools for Confident Environmental Monitoring in the Pharmaceutical Industry
Recorded the 06-Oct-2021 | Webinar
Careful product design and controlled manufacturing of culture media can enable high levels of confidence in environmental monitoring results. New Thermo…
Register for free
Microaerobic Fermentation of Lactobacillus acidophilus
Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note
We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural…
Removing Aggregates of an Acidic Monoclonal Antibody
Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper
CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification….
Show more
On-demand webinars
More promotional features
Sign up to our free newsletter and get the latest news sent direct to your inbox



More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported